In 2 weeks they are NOT showing the 12 month results; those are before end of june (1/2 half of 2013). In two weeks they will talk about the secondary endpoints of the first six month trial and explain why their results with biopsy did not meet statistical significance. They will also talk about Pompes disease.
If the secondary end points show a statistical significance such as urinary GL3 and GFR and then show an improvement in biopsy results at twelve months then the trial is back on track. Additionally with Pompes look for some colour on their efforts on their formulation and its subq version.